What Is CAR-T Cell Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of immunotherapy that uses a patient's own immune cells to fight cancer. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, CAR-T therapy is "precision medicine" — it targets specific proteins found on cancer cell surfaces.
The process involves collecting T-cells (a type of white blood cell) from the patient, genetically engineering them in a laboratory to produce chimeric antigen receptors (CARs), and then infusing these supercharged cells back into the patient. The modified T-cells can then identify, attach to, and destroy cancer cells throughout the body.
CAR-T therapy has shown remarkable results in treating certain blood cancers, particularly B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), with complete remission rates of 40-60% in patients who had exhausted all other treatment options.
How the Treatment Process Works
Leukapheresis
T-cells are collected from your blood through a process similar to blood donation (3-4 hours).
CAR-T Manufacturing
Your T-cells are genetically modified in a specialized laboratory to produce CARs that target cancer cells.
Lymphodepletion
A short course of chemotherapy prepares your immune system by reducing existing lymphocytes.
CAR-T Infusion
The modified cells are infused back into your body. The infusion takes about 30 minutes.
Monitoring
Close monitoring for side effects (CRS, neurotoxicity) in the hospital ICU or dedicated ward.
Cost Comparison: China vs Europe
| Item | China (USD) | Europe (EUR) | Savings |
|---|---|---|---|
| CAR-T Manufacturing | $21,000-49,000 | €200,000-300,000 | 65-75% |
| Hospitalization (3-4 weeks) | $4,200-11,200 | €30,000-50,000 | 60-80% |
| Pre-treatment Assessment | $1,400-2,800 | €5,000-10,000 | 60-70% |
| Total Estimated | $28,000-70,000 | €250,000-350,000 | 60-70% |
* Prices are estimates for reference. Actual costs vary by hospital, specific product, and individual.
Top Hospitals for CAR-T in China
Common Questions
Who is eligible for CAR-T therapy?
CAR-T therapy is primarily approved for certain blood cancers including B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Patients must have relapsed or refractory disease after at least two prior lines of therapy. Your eligibility will be assessed based on cancer type, prior treatments, overall health, and organ function.
What are the risks of CAR-T therapy?
The main risks include Cytokine Release Syndrome (CRS), which occurs in 50-80% of patients and ranges from mild flu-like symptoms to severe inflammatory responses. Neurotoxicity (ICANS) occurs in 20-40% of patients. Both are typically manageable in experienced centers. Other risks include prolonged B-cell aplasia, infections, and low blood counts.
How long does the entire CAR-T process take?
The complete process from initial consultation to discharge typically takes 6-8 weeks: 1-2 weeks for assessment and leukapheresis, 2-3 weeks for CAR-T cell manufacturing, 1 week for lymphodepletion chemotherapy, and 2-3 weeks for post-infusion monitoring.